Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 01/16/2007, Updated: 10/23/2007) - In this trial, colorectal cancer patients with six or fewer hepatic metastases will undergo primary surgery and/or ablation and then be treated with oxaliplatin and capecitabine. Half of the patients will receive additional chemotherapy consisting of floxuridine pumped directly into their livers through an arterial catheter and pump.
Preventing Delayed Nausea in Breast Cancer Patients
(Posted: 10/23/2007) - In this trial, different combinations of drugs will be tested to see which is most effective in preventing delayed nausea in women undergoing chemotherapy for breast cancer.
Regional Chemotherapy for Inoperable Liver Metastases
(Posted: 10/09/2007) - In this trial, doctors are testing a method of delivering chemotherapy regionally to the liver called percutaneous isolated hepatic arterial perfusion (PHP) in patients with liver metastases from ocular (eye) or cutaneous (skin) melanoma.
Pilot Study of Erlotinib to Treat NSCLC
(Posted: 06/07/2005, Updated: 10/01/2007) - In this study, researchers hope to identify tumor characteristics associated with responses to treatment with the drug erlotinib that may be predictors of a survival advantage. The study will also test erlotinib as a first-line therapy for advanced NSCLC.
HIV Protease Inhibitor Therapy for Liposarcoma
(Posted: 09/11/2007) - In this trial, researchers will test an HIV protease inhibitor called nelfinavir in patients with advanced liposarcoma to see if it helps shrink their tumors. Nelfinavir has shown the ability to inhibit liposarcoma cells in laboratory studies.